PDF(Pubmed)
Abstract：
UNASSIGNED: The US Centers for Disease Control and Prevention recommends HIV testing every 3 months in oral PrEP users. We performed a national assessment of HIV testing compliance among oral PrEP users.
UNASSIGNED: We analyzed 408 910 PrEP prescriptions issued to 39 809 PrEP users using a national insurance claims database that contained commercial and Medicaid claims. We identified PrEP use based on pharmacy claims and outpatient diagnostic coding. We evaluated the percentage of PrEP prescription refills without HIV testing (identified by CPT codes) within the prior 3, 6, and 12 months using time to event methods. We performed subgroup and multivariate analyses by age, gender, race, insurance type, and geography.
UNASSIGNED: Of 39 809 persons, 36 197 were commercially insured, 3612 were Medicaid-insured, and 96% identified as male; the median age (interquartile range) was 34 (29-44) years, and the Medicaid-insured PrEP users were 24% Black/African American, 44% White, and 9% Hispanic/Latinx. Within the prior 3, 6, and 12 months, respectively, the percentage of PrEP prescription fills in individuals without HIV Ag/Ab testing was 34.3% (95% CI, 34.2%-34.5%), 23.8% (95% CI, 23.7%-23.9%), and 16.6% (95% CI, 16.4%-16.7%), and the percentage without any type of HIV test was 25.8% (95% CI, 25.6%-25.9%), 14.6% (95% CI, 14.5%-14.7%), and 7.8% (95% CI, 7.7%-7.9%).
UNASSIGNED: Approximately 1 in 3 oral PrEP prescriptions were filled in persons who had not received an HIV Ag/Ab test within the prior 3 months, with evidence of health disparities. These findings inform clinical PrEP monitoring efforts and compliance with national HIV testing guidance to monitor PrEP users.
UNASSIGNED: We analyzed 408 910 PrEP prescriptions issued to 39 809 PrEP users using a national insurance claims database that contained commercial and Medicaid claims. We identified PrEP use based on pharmacy claims and outpatient diagnostic coding. We evaluated the percentage of PrEP prescription refills without HIV testing (identified by CPT codes) within the prior 3, 6, and 12 months using time to event methods. We performed subgroup and multivariate analyses by age, gender, race, insurance type, and geography.
UNASSIGNED: Of 39 809 persons, 36 197 were commercially insured, 3612 were Medicaid-insured, and 96% identified as male; the median age (interquartile range) was 34 (29-44) years, and the Medicaid-insured PrEP users were 24% Black/African American, 44% White, and 9% Hispanic/Latinx. Within the prior 3, 6, and 12 months, respectively, the percentage of PrEP prescription fills in individuals without HIV Ag/Ab testing was 34.3% (95% CI, 34.2%-34.5%), 23.8% (95% CI, 23.7%-23.9%), and 16.6% (95% CI, 16.4%-16.7%), and the percentage without any type of HIV test was 25.8% (95% CI, 25.6%-25.9%), 14.6% (95% CI, 14.5%-14.7%), and 7.8% (95% CI, 7.7%-7.9%).
UNASSIGNED: Approximately 1 in 3 oral PrEP prescriptions were filled in persons who had not received an HIV Ag/Ab test within the prior 3 months, with evidence of health disparities. These findings inform clinical PrEP monitoring efforts and compliance with national HIV testing guidance to monitor PrEP users.
摘要：
■美国疾病控制和预防中心建议每3个月在口服PrEP使用者中进行HIV检测。我们对口服PrEP使用者的HIV检测合规性进行了全国性评估。
■我们使用包含商业和医疗补助索赔的国家保险索赔数据库，分析了向39809PrEP用户发行的408910PrEP处方。我们根据药房声明和门诊诊断编码确定了PrEP的使用。我们使用事件发生时间方法评估了前3、6和12个月内未进行HIV检测（通过CPT代码识别）的PrEP处方补充的百分比。我们按年龄进行了亚组和多变量分析，性别,种族,保险类型,和地理。
■在39809人中，36197是商业保险，3612是医疗补助保险，96%为男性；中位年龄(四分位数间距)为34(29-44)岁，医疗补助保险的PrEP用户是24%的黑人/非洲裔美国人，44％白色，和9%的西班牙裔/拉丁裔。在前3、6和12个月内，分别,未进行HIVAg/Ab检测的患者的PrEP处方填写百分比为34.3％（95％CI，34.2％-34.5％），23.8%（95%CI，23.7%-23.9%），和16.6%（95%CI，16.4%-16.7%），没有任何类型的HIV检测的百分比为25.8%（95%CI，25.6%-25.9%），14.6%（95%CI，14.5%-14.7%），和7.8%（95%CI，7.7%-7.9%）。
■在过去3个月内未接受HIVAg/Ab测试的人中，约有三分之一的口服PrEP处方被填写，有健康差异的证据。这些发现为临床PrEP监测工作以及遵守国家HIV检测指南以监测PrEP用户提供了信息。
■我们使用包含商业和医疗补助索赔的国家保险索赔数据库，分析了向39809PrEP用户发行的408910PrEP处方。我们根据药房声明和门诊诊断编码确定了PrEP的使用。我们使用事件发生时间方法评估了前3、6和12个月内未进行HIV检测（通过CPT代码识别）的PrEP处方补充的百分比。我们按年龄进行了亚组和多变量分析，性别,种族,保险类型,和地理。
■在39809人中，36197是商业保险，3612是医疗补助保险，96%为男性；中位年龄(四分位数间距)为34(29-44)岁，医疗补助保险的PrEP用户是24%的黑人/非洲裔美国人，44％白色，和9%的西班牙裔/拉丁裔。在前3、6和12个月内，分别,未进行HIVAg/Ab检测的患者的PrEP处方填写百分比为34.3％（95％CI，34.2％-34.5％），23.8%（95%CI，23.7%-23.9%），和16.6%（95%CI，16.4%-16.7%），没有任何类型的HIV检测的百分比为25.8%（95%CI，25.6%-25.9%），14.6%（95%CI，14.5%-14.7%），和7.8%（95%CI，7.7%-7.9%）。
■在过去3个月内未接受HIVAg/Ab测试的人中，约有三分之一的口服PrEP处方被填写，有健康差异的证据。这些发现为临床PrEP监测工作以及遵守国家HIV检测指南以监测PrEP用户提供了信息。
